Literature DB >> 29036392

Update From the Advisory Committee on Immunization Practices.

Sean T O'Leary1, David W Kimberlin2.   

Abstract

The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, and each member's term is 4 years. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (Carrie L. Byington and D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present as liaisons to the ACIP. The ACIP met on June 21 to 22, 2017, to discuss catch-up vaccination for hepatitis A vaccine, influenza surveillance, influenza vaccine effectiveness, herpes zoster vaccine, the effect of varicella vaccination on the incidence of herpes zoster, meningococcal disease in patients taking eculizumab, and considerations for a potential third dose of measles, mumps, and rubella (MMR) vaccine to combat ongoing mumps outbreaks. Updates on dengue virus epidemiology, Zika virus vaccines, anthrax vaccine, yellow fever vaccine, and the Vaccine Adverse Event Reporting System were given also.
© The Author 2017. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ACIP; CDC; immunization

Mesh:

Substances:

Year:  2017        PMID: 29036392     DOI: 10.1093/jpids/pix066

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  3 in total

Review 1.  Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs.

Authors:  Elissa R Engel; Jolan E Walter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

3.  Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Authors:  Gérard Socié; Marie-Pierre Caby-Tosi; Jing L Marantz; Alexander Cole; Camille L Bedrosian; Christoph Gasteyger; Arshad Mujeebuddin; Peter Hillmen; Johan Vande Walle; Hermann Haller
Journal:  Br J Haematol       Date:  2019-02-15       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.